Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV Drug Consortium Wins €4M EU Funding

The project, known as HIVINNOV, is being coordinated by Mutabilis and aims to develop a class of antiretrovirals that don’t target HIV directly, but rather impact on the interactions between virus and host.

Published
18 September 2012
From
Genetic Engineering News
Gilead's HIV pill could be market leader in 3-5 years: JP Morgan

J.P. Morgan Securities raised its price target on Gilead Sciences Inc to $75 from $70, saying the company's new HIV pill Stribild could emerge as a "market leader" in three to five years, sending the drugmaker's shares to a life-high.

Published
18 September 2012
From
CNBC
amfAR Announces New Round of Cure-Focused Research Grants

On the heels of the XIX International AIDS Conference and progress reported there on the search for a cure for HIV/AIDS, amfAR, The Foundation for AIDS Research on Friday announced three new grants to research teams as part of the Foundation’s two-year-old amfAR Research Consortium on HIV Eradication (ARCHE).

Published
18 September 2012
From
AmFAR
ART for life cost effective for prevention of mother-to-child transmission in Uganda

Combination antiretroviral therapy (ART) provided to all pregnant women with HIV who have CD4 cell counts under 350 cells/mm3 (World Health Organization Option B) in Uganda appears to

Published
18 September 2012
By
Carole Leach-Lemens
Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

The integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and

Published
17 September 2012
By
Liz Highleyman
Dolutegravir combo beats Atripla for effectiveness and tolerability

The experimental integrase inhibitor dolutegravir combined with abacavir/lamivudine (Kivexa or Epzicom) demonstrated statistically superior antiviral efficacy than the popular Atripla single-tablet regimen for first-line HIV treatment, largely because fewer people

Published
14 September 2012
By
Liz Highleyman
Mutation breaks HIV's resistance to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

Published
14 September 2012
From
Science Daily
New HIV Drugs Promising but Unworkable

A new series of nucleotide competing reverse transcriptase inhibitors (NcRTIs) may represent a novel treatment option for HIV-1 infected patients but may be limited by toxicity given early animal data.

Published
14 September 2012
From
MedPage Today
Long-Lasting HIV Drug Could Change Therapy

An extremely long-lasting anti-HIV drug has the potential to alter both treatment and prevention of the virus, researchers said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. The investigational integrase inhibitor S/GSK744 might need to be given only every 3 months.

Published
13 September 2012
From
MedPage Today
British HIV Association proposes new standards for care

BHIVA (The British HIV Association), the UK's leading association of HIV care professionals, is seeking views on new proposals for care for people with HIV in the UK. The proposals include twelve crucial areas for care, including offering people an HIV test, defining what HIV care should be available through clinical services, and the involvement of people living with HIV in the design and delivery of care and how information should be collected.

Published
13 September 2012
From
BHIVA press release

Filter by country